Jamjoom Pharmaceuticals Factory Co. announces its Interim Financial results for the Period Ending on 2025-03-31 ( Three Months )

30 April 2025 08:00 AM

JAMJOOM PHARMA 4015 4.50% 176.40 7.60

Element List	Current Quarter	Similar quarter for previous year	%Change	Previous Quarter	% Change
Sales/Revenue	457.53	385.46	18.697	259.7	76.176
Gross Profit (Loss)	292.85	249.4	17.421	158.51	84.751
Operational Profit (Loss)	158.18	127.28	24.277	54.01	192.871
Net profit (Loss)	157.03	102.97	52.5	51.61	204.262
Total Comprehensive Income	158.11	57.17	176.561	45.98	243.866
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Current Period	Similar period for previous year	%Change
Total Shareholders Equity (after Deducting Minority Equity)	1,546.52	1,461.5	5.817
Profit (Loss) per Share	2.24	1.47
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Amount	Percentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value	-	-
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Explanation
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is	Revenue for the current quarter has increased by 18.7% compared to the same quarter of the last year, supported by strong performance across key therapeutic areas - notably Ophthalmology, Dermatology and General Medicine - and key geographies including KSA, Gulf and Iraq.
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is	Net profit increased by 52.5% during the current quarter compared to the same quarter of the last year primarily driven by enhanced operational efficiencies achieved through an effective strategy to optimize profitability and control operating costs. Additionally, earnings were supported by a profit contribution from the joint venture in Algeria, as well as significantly lower finance costs as compared to 1Q 2024, which had a significant depreciation impact of the Egyptian Pound (EGP).
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is	Revenue for the current quarter has increased by 76.2% compared to 4Q 2024, primarily driven by higher demand across key markets and therapeutic areas, as well as the impact of lower sales in the fourth quarter compared to other quarters of the year due to strategic reasons.
The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is	The Company’s net profit increased by 204.3% during the current quarter compared to the 4Q 2024, driven by higher sales and more efficient absorption of operating expenses resulting in strong operating leverage.
Statement of the type of external auditor's report	Unmodified conclusion
Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion)	None
Reclassification of Comparison Items	Certain figures for the prior period have been reclassified to conform to the presentation in the current period.
Additional Information	Please refer to the attached Press Release for detailed information on the 1Q 2025 results.
Attached Documents